Hepatitis B and C in African Americans: Current status and continued challenges

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 5, 2014, Pages 738-748

  Forde, Kimberly A ^a,b   Tanapanpanit, Orapin ^a   Reddy, K Rajender ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

African American; Black; Disparities; Hepatitis B; Hepatitis C

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON;

AFRICAN AMERICAN; ANTIVIRAL THERAPY; ARTICLE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HISTORY; HOST; HUMAN; INCIDENCE; INFECTION RISK; LIVER TRANSPLANTATION; MONOTHERAPY; PREVALENCE; TREATMENT OUTCOME; UNITED STATES;

AFRICAN AMERICANS; HEPATITIS B; HEPATITIS C; HUMANS; UNITED STATES;

EID: 84898831733     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.06.006     Document Type: Article

References (99)

1. Ioannou G.N. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011, 154:319-328.
2. Weinbaum C.M., Williams I., Mast E.E., et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008, 57:1-20.
3. Kowdley K.V., Wang C.C., Welch S., et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012, 56:422-433.
4. Cohen C., Holmberg S.D., McMahon B.J., et al. Is chronic hepatitis B being undertreated in the United States?. JViral Hepat 2011, 18:377-383.
5. Centers for Disease Control and Prevention. Hepatitis B information for health professionals, 2012. Available at:. Accessed November 17,2012. http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm.
6. McQuillan G.M., Coleman P.J., Kruszon-Moran D., et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999, 89:14-18.
7. McQuillan G.M., Kruszon-Moran D., Kottiri B.J., et al. Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994. Am J Public Health 2004, 94:1952-1958.
8. McMahon B.J. Natural history of chronic hepatitis B. Clin Liver Dis 2010, 14:381-396.
9. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. NEngl J Med 1999, 340:745-750.
10. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127(Suppl 1):S27-S34.
11. Yu L., Sloane D.A., Guo C., et al. Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol 2006, 4:355-360.
12. Kew M.C., Kramvis A., Yu M.C., et al. Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans. JMed Virol 2005, 75:513-521.
13. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
14. Kew M.C. Hepatocellular carcinoma in African Blacks: recent progress in etiology and pathogenesis. World J Hepatol 2010, 2:65-73.
15. Kew M.C., Macerollo P. Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks. Gastroenterology 1988, 94:439-442.
16. Kew M.C., Marcus R., Geddes E.W. Some characteristics of Mozambican Shangaans with primary hepatocellular cancer. SAfr Med J 1977, 51:306-309.
17. Umoh N.J., Lesi O.A., Mendy M., et al. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver Int 2011, 31:215-221.
18. Chen C.H., Eng H.L., Lee C.M., et al. Correlations between hepatitis B virus genotype and cirrhotic or non-cirrhotic hepatoma. Hepatogastroenterology 2004, 51:552-555.
19. Chu C.J., Keeffe E.B., Han S.H., et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003, 125:444-451.
20. Kao J.H., Chen P.J., Lai M.Y., et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000, 118:554-559.
21. Kao J.H., Wu N.H., Chen P.J., et al. Hepatitis B genotypes and the response to interferon therapy. JHepatol 2000, 33:998-1002.
22. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. NEngl J Med 2005, 352:2682-2695.
23. Wai C.T., Chu C.J., Hussain M., et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002, 36:1425-1430.
24. Cheong J.Y., Cho S.W., Hwang I.L., et al. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. JGastroenterol Hepatol 2006, 21:1163-1169.
25. Peng X.M., Huang Y.S., Ma H.H., et al. Interleukin-10 promoter polymorphisms are associated with the mode and sequel of HBeAg seroconversion in patients with chronic hepatitis B virus infection. Liver Int 2006, 26:326-333.
26. Truelove A.L., Oleksyk T.K., Shrestha S., et al. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. Int J Immunogenet 2008, 35:255-264.
27. Oleksyk T.K., Thio C.L., Truelove A.L., et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005, 6:347-357.
28. Lau D.T., Everhart J., Kleiner D.E., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997, 113:1660-1667.
29. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
30. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. NEngl J Med 1999, 341:1256-1263.
31. Perrillo R.P., Lai C.L., Liaw Y.F., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002, 36:186-194.
32. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. NEngl J Med 2003, 348:808-816.
33. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. NEngl J Med 2003, 348:800-807.
34. Dienstag J.L., Cianciara J., Karayalcin S., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003, 37:748-755.
35. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. NEngl J Med 2004, 351:1206-1217.
36. Kuo A., Dienstag J.L., Chung R.T. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004, 2:266-272.
37. Chang T.T., Gish R.G., Hadziyannis S.J., et al. Adose-ranging study ofthe efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129:1198-1209.
38. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743-1751.
39. Chang T.T., Gish R.G., de Man R., et al. Acomparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. NEngl J Med 2006, 354:1001-1010.
40. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. NEngl J Med 2006, 354:1011-1020.
41. Marcellin P., Chang T.T., Lim S.G., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750-758.
42. Marcellin P., Heathcote E.J., Buti M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. NEngl J Med 2008, 359:2442-2455.
43. Leung N., Peng C.Y., Hann H.W., et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009, 49:72-79.
44. Liaw Y.F., Gane E., Leung N., et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.
45. Widjaja D., Yarlagadda S., Singu B.S., et al. Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital. JNatl Med Assoc 2007, 99:384-388.
46. Reid A.E., Resnick M., Chang Y., et al. Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transpl 2004, 10:834-841.
47. Moylan C.A., Brady C.W., Johnson J.L., et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008, 300:2371-2378.
48. Kim W.R., Poterucha J.J., Kremers W.K., et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004, 10:968-974.
49. Bzowej N., Han S., Degertekin B., et al. Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl 2009, 15:1010-1020.
50. Seeff L.B., Miller R.N., Rabkin C.S., et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000, 132:105-111.
51. Pyrsopoulos N., Jeffers L. Hepatitis C in African Americans. JClin Gastroenterol 2007, 41:185-193.
52. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. NEngl J Med 1999, 341:556-562.
53. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
54. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
55. Ly K.N., Jian X., Klevens R.M., et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012, 156. 271-W-52.
56. Wiley T.E., Brown J., Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002, 97:700-706.
57. Reddy K.R., Hoofnagle J.H., Tong M.J., et al. Racial differences in responses to therapy with interferon in chronic hepatitis C: Consensus Interferon Study Group. Hepatology 1999, 30:787-793.
58. Kohla M., Iwata S., Ea R., et al. Histological versus clinical cirrhosis in chronic hepatitis C: does race/ethnicity really matter?. Dig Dis Sci 2012, 57:771-776.
59. Crosse K., Umeadi O.G., Anania F.A., et al. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2004, 2:463-468.
60. Terrault N.A., Im K., Boylan R., et al. Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol 2008, 6:1403-1411.
61. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273.
62. Simard E.P., Ward E.M., Siegel R., et al. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012, 62:118-128.
63. Alberti A., Vario A., Ferrari A., et al. Review article: chronic hepatitis C-natural history and cofactors. Aliment Pharmacol Ther 2005, 22(Suppl 2):74-78.
64. Mizokami M., Orito E. Molecular evolution of hepatitis viruses. Intervirology 1999, 42:159-165.
65. Pyrsopoulos N., Jeffers L. Chronic hepatitis C in African Americans. Clin Liver Dis 2005, 9:427-438. vii.
66. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State 2002, 19:1-46.
67. Jeffers L.J., Cassidy W., Howell C.D., et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004, 39:1702-1708.
68. Muir A.J., Bornstein J.D., Killenberg P.G., et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. NEngl J Med 2004, 350:2265-2271.
69. Conjeevaram H.S., Fried M.W., Jeffers L.J., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
70. Donlin M.J., Cannon N.A., Yao E., et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. JVirol 2007, 81:8211-8224.
71. Lok A.S., Gardiner D.F., Lawitz E., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. NEngl J Med 2012, 366:216-224.
72. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
73. Suppiah V., Moldovan M., Ahlenstiel G., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
74. Tanaka Y., Nishida N., Sugiyama M., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-1109.
75. Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129.
76. McCarthy J.J., Li J.H., Thompson A., et al. Replicated association between an IL28B gene variant and a sustained response topegylated interferon and ribavirin. Gastroenterology 2010, 138:2307-2314.
77. Rauch A., Kutalik Z., Descombes P., et al. Genetic variation in IL28B isassociated with chronic hepatitis C and treatment failure: agenome-wide association study. Gastroenterology 2010, 138:1338-1345.
78. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. NEngl J Med 2002, 347:975-982.
79. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
80. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group. NEngl J Med 1998, 339:1485-1492.
81. Poynard T., Bedossa P., Chevallier M., et al. Acomparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis: Multicenter Study Group. NEngl J Med 1995, 332:1457-1462.
82. Theodore D., Shiffman M.L., Sterling R.K., et al. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci 2003, 48:140-145.
83. McHutchison J.G., Poynard T., Pianko S., et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000, 119:1317-1323.
84. Burton M.J., Passarella M.J., McGuire B.M. Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers. South Med J 2012, 105:431-436.
85. Melia M.T., Muir A.J., McCone J., et al. Racial differences in hepatitis C treatment eligibility. Hepatology 2011, 54:70-78.
86. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. NEngl J Med 2011, 365:1014-1024.
87. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. NEngl J Med 2011, 364:1195-1206.
88. El-Serag H.B., Davila J.A., Petersen N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
89. Nguyen M.H., Whittemore A.S., Garcia R.T., et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004, 2:820-824.
90. Kemmer N., Neff G., Secic M., et al. Ethnic differences in hepatocellular carcinoma: implications for liver transplantation. Dig Dis Sci 2008, 53:551-555.
91. Thuluvath P.J., Maheshwari A., Thuluvath N.P., et al. Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus. Liver Transpl 2009, 15:754-762.
92. Nair S., Eustace J., Thuluvath P.J. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002, 359:287-293.
93. Charlton M., Seaberg E., Wiesner R., et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28:823-830.
94. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. NEngl J Med 2011, 364:1207-1217.
95. Hezode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. NEngl J Med 2009, 360:1839-1850.
96. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. NEngl J Med 2009, 360:1827-1838.
97. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. NEngl J Med 2010, 362:1292-1303.
98. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
99. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. NEngl J Med 2011, 364:2405-2416.